Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alaunos TherapeuticsTCRT +5.01%27 3-Year EPS without NRI Growth Rate is 56.30% as of Jun. 2026, which is 279% above its 10-year median of 14.85. GuruFocus rates TCRT with a GF Score™ of 27/100 and a GF Value™ of $0.82 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,155 Biotechnology companies, Alaunos Therapeutics ranks better than 88.4% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 56.30% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 51.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Alaunos Therapeutics was 67.10% per year. The lowest was -277.40% per year. And the median was 14.85% per year.
Alaunos Therapeutics (NAS:TCRT) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Alaunos Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
TCRT vs MBIO, REVB, GRI: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Alaunos Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alaunos Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Alaunos Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Alaunos Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 56.30% mean?
Alaunos Therapeutics (TCRT) has a 3-Year EPS without NRI Growth Rate of 56.30% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Alaunos Therapeutics and its competitors. This is 279% above median its historical median of 14.85. According to the industry distribution chart, Alaunos Therapeutics ranks #134 out of 1155 companies in the Biotechnology industry, placing it in the top 11.6%.
Is Alaunos Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Alaunos Therapeutics' current 3-Year EPS without NRI Growth Rate of 56.30% is 279% above median its 10-year median of 14.85. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.00. Alaunos Therapeutics' value of 56.30% is 251.9% above this industry median. Based on the distribution chart, Alaunos Therapeutics ranks #134 out of 1155 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alaunos Therapeutics has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alaunos Therapeutics' 3-Year EPS without NRI Growth Rate compare to MBIO and REVB?
According to the Biotechnology industry distribution chart, Alaunos Therapeutics ranks #134 out of 1155 companies for 3-Year EPS without NRI Growth Rate. This places Alaunos Therapeutics in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 16.00. Alaunos Therapeutics' value of 56.30% is 251.9% above this benchmark. While the company's 10-year median is 14.85 vs. the industry median of 16.00, Alaunos Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.00, based on 1,155 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alaunos Therapeutics's current 3-Year EPS without NRI Growth Rate of 56.30% is 251.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Alaunos Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alaunos Therapeutics's current 3-Year EPS without NRI Growth Rate is 56.30%, which is 279% above median its own 10-year median of 14.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alaunos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Alaunos Therapeutics (TCRT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.82, compared to a current price of $1.26 — trading 53.7% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 56.30%, which is 279% above median its 10-year median of 14.85 and 251.9% above the Biotechnology industry median of 16.00. Alaunos Therapeutics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Alaunos Therapeutics (TCRT), the current 3-Year EPS without NRI Growth Rate is 56.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alaunos Therapeutics (TCRT) Overvalued in 2026?
Based on GuruFocus' analysis, Alaunos Therapeutics stock appears to be overvalued.
The current stock price of $1.26 is trading 53.7% above its estimated GF Value™ of $0.82.
GuruFocus considers Alaunos Therapeutics to be Significantly Overvalued.
Key valuation signals for TCRT:
3-Year EPS without NRI Growth Rate: 56.30% (279% above median its 10-year median of 14.85)
GF Value™: $0.82 vs. price of $1.26 (53.7% above fair value)
Industry Position: 251.9% above the Biotechnology median (#134 of 1155)
No single metric tells the full story. See the TCRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
27GF Score
Get the complete analysis for TCRT
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TCRT has been successfully added to your 
